Efpia
The European Federation of Pharmaceutical Industries and Associations (EFPIA), headquartered in Belgium, represents the pharmaceutical industry across Europe. Founded in 1978, EFPIA plays a pivotal role in advocating for the interests of its members, which include leading pharmaceutical companies and national associations. The organisation focuses on key areas such as research and development, access to medicines, and healthcare policy. With a commitment to innovation, EFPIA supports initiatives that enhance patient access to high-quality treatments while promoting sustainable healthcare systems. Its unique position as a bridge between the pharmaceutical industry and European policymakers enables it to influence critical discussions on health and medicine. Notable achievements include significant contributions to public health and the advancement of regulatory frameworks that benefit both patients and the industry.
DitchCarbon Score
How does Efpia's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Other Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Efpia's score of 10 is higher than 74% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Efpia's reported carbon emissions
In 2022, Efpia reported significant carbon emissions totalling approximately 97,100,000,000 kg CO2e, with emissions distributed across all three scopes: 8,900,000,000 kg CO2e for Scope 1, 4,900,000,000 kg CO2e for Scope 2, and a substantial 97,100,000,000 kg CO2e for Scope 3. This data highlights the organisation's extensive carbon footprint, particularly in Scope 3 emissions, which often represent the largest share of total emissions for companies in the pharmaceutical sector. Efpia has made strides in reducing its emissions intensity in recent years, with a decrease from 0.024 kg CO2e per EUR in 2019 to 0.0191 kg CO2e per EUR in 2021 for Scope 1 and 2 emissions related to pharmaceutical products. However, there are currently no publicly disclosed reduction targets or climate pledges, indicating a potential area for future commitment and improvement in their climate strategy. As a key player in the pharmaceutical industry, Efpia's climate commitments and emissions data are crucial for understanding its impact on global carbon emissions and its role in addressing climate change.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project| 2022 | |
|---|---|
| Scope 1 | 8,900,000,000 |
| Scope 2 | 4,900,000,000 |
| Scope 3 | 97,100,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Efpia is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
